The JAK2 V617F (exon 14) mutation analysis can be used in conjunction with bone marrow histology and cytogenetic analysis to assist in the diagnosis of myeloproliferative neoplasma (MPN). The JAK2 V617F mutation is found in almost all patients with polycythemia vera (PV) and in nearly one-half of those with idiopathic myelofibrosis (IMF) and with essential thrombocythemia (ET). A small percentage (~3.3%) of JAK2 mutation positive patient contain other non-V617F mutations within exons 12 to 15.
Lavender (EDTA), Na heparin (green), yellow (ACD) topped tube or sterile via
Reverse transcription polymerase chain reaction RT-PCR and Sanger sequencing
An interpretive report will be provided